116 related articles for article (PubMed ID: 21391890)
1. Brivanib alaninate for cancer.
Diaz-Padilla I; Siu LL
Expert Opin Investig Drugs; 2011 Apr; 20(4):577-86. PubMed ID: 21391890
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.
Marathe PH; Kamath AV; Zhang Y; D'Arienzo C; Bhide R; Fargnoli J
Cancer Chemother Pharmacol; 2009 Dec; 65(1):55-66. PubMed ID: 19396600
[TBL] [Abstract][Full Text] [Related]
3. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
Ayers M; Fargnoli J; Lewin A; Wu Q; Platero JS
Cancer Res; 2007 Jul; 67(14):6899-906. PubMed ID: 17638901
[TBL] [Abstract][Full Text] [Related]
4. Brivanib, a novel dual VEGF-R2/bFGF-R inhibitor.
Dempke WC; Zippel R
Anticancer Res; 2010 Nov; 30(11):4477-83. PubMed ID: 21115896
[TBL] [Abstract][Full Text] [Related]
5. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate.
Shiang CY; Qi Y; Wang B; Lazar V; Wang J; Fraser Symmans W; Hortobagyi GN; Andre F; Pusztai L
Breast Cancer Res Treat; 2010 Oct; 123(3):747-55. PubMed ID: 20024612
[TBL] [Abstract][Full Text] [Related]
6. Metabolic chiral inversion of brivanib and its relevance to safety and pharmacology.
Gong J; Gan J; Masson E; Syed S; Xia YQ; Williams D; Pursley J; Jemal M; Humphreys WG; Iyer RA
Drug Metab Dispos; 2012 Dec; 40(12):2374-80. PubMed ID: 22983304
[TBL] [Abstract][Full Text] [Related]
7. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
[TBL] [Abstract][Full Text] [Related]
8. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215).
Cai ZW; Zhang Y; Borzilleri RM; Qian L; Barbosa S; Wei D; Zheng X; Wu L; Fan J; Shi Z; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Kamath A; Marathe P; D'Arienzo C; Derbin G; Barrish JC; Robl JA; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2008 Mar; 51(6):1976-80. PubMed ID: 18288793
[TBL] [Abstract][Full Text] [Related]
9. A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.
Jonker DJ; Rosen LS; Sawyer MB; de Braud F; Wilding G; Sweeney CJ; Jayson GC; McArthur GA; Rustin G; Goss G; Kantor J; Velasquez L; Syed S; Mokliatchouk O; Feltquate DM; Kollia G; Nuyten DSA; Galbraith S
Ann Oncol; 2011 Jun; 22(6):1413-1419. PubMed ID: 21131369
[TBL] [Abstract][Full Text] [Related]
10. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
Patel RR; Sengupta S; Kim HR; Klein-Szanto AJ; Pyle JR; Zhu F; Li T; Ross EA; Oseni S; Fargnoli J; Jordan VC
Eur J Cancer; 2010 Jun; 46(9):1537-53. PubMed ID: 20303261
[TBL] [Abstract][Full Text] [Related]
11. Brivanib: a review of development.
Chou T; Finn RS
Future Oncol; 2012 Sep; 8(9):1083-90. PubMed ID: 23030483
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
Lin HC; Huang YT; Yang YY; Lee PC; Hwang LH; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Liu RS
J Gastroenterol Hepatol; 2014 May; 29(5):1073-82. PubMed ID: 24325631
[TBL] [Abstract][Full Text] [Related]
13. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
Bhide RS; Lombardo LJ; Hunt JT; Cai ZW; Barrish JC; Galbraith S; Jeyaseelan R; Mortillo S; Wautlet BS; Krishnan B; Kukral D; Malone H; Lewin AC; Henley BJ; Fargnoli J
Mol Cancer Ther; 2010 Feb; 9(2):369-78. PubMed ID: 20103604
[TBL] [Abstract][Full Text] [Related]
14. Metabolism and disposition of [14C]brivanib alaninate after oral administration to rats, monkeys, and humans.
Gong J; Gan J; Caceres-Cortes J; Christopher LJ; Arora V; Masson E; Williams D; Pursley J; Allentoff A; Lago M; Tran SB; Iyer RA
Drug Metab Dispos; 2011 May; 39(5):891-903. PubMed ID: 21289073
[TBL] [Abstract][Full Text] [Related]
15. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases.
El-Khoueiry A; Posey JA; Castillo Ferrando JR; Krishnamurthi SS; Syed S; Kollia G; Walters I; Fischer BS; Masson E
Cancer Chemother Pharmacol; 2013 Jul; 72(1):53-64. PubMed ID: 23719718
[TBL] [Abstract][Full Text] [Related]
16. Lack of effect of brivanib on the pharmacokinetics of midazolam, a CYP3A4 substrate, administered intravenously and orally in healthy participants.
Syed S; Clemens PL; Lathers D; Kollia G; Dhar A; Walters I; Masson E
J Clin Pharmacol; 2012 Jun; 52(6):914-21. PubMed ID: 21659627
[TBL] [Abstract][Full Text] [Related]
17. Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.
Siu LL; Shapiro JD; Jonker DJ; Karapetis CS; Zalcberg JR; Simes J; Couture F; Moore MJ; Price TJ; Siddiqui J; Nott LM; Charpentier D; Liauw W; Sawyer MB; Jefford M; Magoski NM; Haydon A; Walters I; Ringash J; Tu D; O'Callaghan CJ
J Clin Oncol; 2013 Jul; 31(19):2477-84. PubMed ID: 23690424
[TBL] [Abstract][Full Text] [Related]
18. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma.
Park JW; Finn RS; Kim JS; Karwal M; Li RK; Ismail F; Thomas M; Harris R; Baudelet C; Walters I; Raoul JL
Clin Cancer Res; 2011 Apr; 17(7):1973-83. PubMed ID: 21349999
[TBL] [Abstract][Full Text] [Related]
19. Metabolism, excretion, and pharmacokinetics of oral brivanib in patients with advanced or metastatic solid tumors.
Mekhail T; Masson E; Fischer BS; Gong J; Iyer R; Gan J; Pursley J; Patricia D; Williams D; Ganapathi R
Drug Metab Dispos; 2010 Nov; 38(11):1962-6. PubMed ID: 20671097
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.
Borzilleri RM; Zheng X; Qian L; Ellis C; Cai ZW; Wautlet BS; Mortillo S; Jeyaseelan R; Kukral DW; Fura A; Kamath A; Vyas V; Tokarski JS; Barrish JC; Hunt JT; Lombardo LJ; Fargnoli J; Bhide RS
J Med Chem; 2005 Jun; 48(12):3991-4008. PubMed ID: 15943473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
